2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
[HTML][HTML] Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring
S Susen, CA Tacquard, A Godon, A Mansour… - Critical care, 2020 - Springer
COVID-19 is an infection induced by the SARS-CoV-2 coronavirus, and severe forms can
lead to acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) …
lead to acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) …
[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2022 - ncbi.nlm.nih.gov
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
Vascular endothelial damage in the pathogenesis of organ injury in severe COVID-19
A Dupont, A Rauch, S Staessens… - … and Vascular Biology, 2021 - Am Heart Assoc
Objective: Whether endotheliopathy only mirrors coronavirus disease 2019 (COVID-19)
severity or plays an intrinsic role in microvascular thrombosis and organ failure remains …
severity or plays an intrinsic role in microvascular thrombosis and organ failure remains …
Role of aspirin in primary prevention of cardiovascular disease
C Patrono, C Baigent - Nature Reviews Cardiology, 2019 - nature.com
The benefits of aspirin therapy for the secondary prevention of cardiovascular disease
clearly outweigh the risks of bleeding, and low-dose aspirin is uniformly recommended in …
clearly outweigh the risks of bleeding, and low-dose aspirin is uniformly recommended in …
[HTML][HTML] Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
A Rauch, J Labreuche, F Lassalle, J Goutay… - Journal of Thrombosis …, 2020 - Elsevier
Background Hypercoagulability seems to contribute to SARS‐CoV‐2 pneumonia
pathogenesis. However, age and metabolic syndrome are potential confounders when …
pathogenesis. However, age and metabolic syndrome are potential confounders when …
[HTML][HTML] Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction
Background Therapies that could further prevent the development of heart failure (HF) and
other cardiovascular and metabolic events in patients with recent myocardial infarction (MI) …
other cardiovascular and metabolic events in patients with recent myocardial infarction (MI) …
[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2022 - thelancet.com
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
Impact of high-dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia
C Tacquard, A Mansour, A Godon, J Godet, J Poissy… - Chest, 2021 - Elsevier
Background Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2
infection, several scientific societies have proposed to increase the dose of preventive …
infection, several scientific societies have proposed to increase the dose of preventive …
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
F Andreotti, T Geisler, JP Collet, B Gigante… - European Heart …, 2023 - academic.oup.com
The first international guidance on antithrombotic therapy in the elderly came from the
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …